The company is a listed pharmaceutical group enterprise integrating R&D, production and marketing. The company's predecessor, Shanxi Qianyuan Pharmaceutical Co., Ltd., was established on March 23, 2005. Since then, it has grown from a small pharmaceutical company with only 100 employees and 2 main products. It has provided products and services across 34 provincial administrative regions across the country, and has gradually expanded its business to the international market and precision medicine. The company changed its name to Shanxi Qianyuan Pharmaceutical Co., Ltd. in June 2010 and was successfully listed on the Shenzhen Stock Exchange GEM on August 19, 2011. In September 2014, the company changed its name to Shanxi Qianyuan Pharmaceutical Group Co., Ltd. It is mainly engaged in R&D, production and sales of pharmaceuticals and health foods, medical and health services and commercial business such as medical diagnosis, gene preservation, and pregnancy environment testing. The company's pharmaceutical product categories include anti-infectives, anti-allergic drugs, respiratory drugs, urinary system drugs, nephropathy drugs, pediatric drugs, cardiovascular drugs, antidepressants, pharmaceutical raw materials and intermediates. The main varieties are: fosfomycin, tamsulosin hydrochloride sustained-release capsules, ebastine tablets, cinacarcetin hydrochloride tablets, vitamin AD drops, ambroxol hydrochloride dispersible tablets, montmorillonite powder, fluoxetine hydrochloride capsules, apixaban tablets, rivacaban tablets, glucosamine hydrochloride (glucosamine hydrochloride) APIs), etc.; The company's health food mainly includes varieties such as Baoling Gengbao oral liquid, etc., and the company's medical and health services include Medical tests, gene preservation services, etc.
相关临床试验
0
0 进行中
药物批准
181
批准总数
监管机构
1
监管机构数
成立时间
2005
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无资讯文章